MediGene AG Forecast, price target & analysts
€0.13
0.00%
day before yesterday
Xetra,
May 07, 09:00 am CET
MediGene AG Target price 2025 - Analyst rating & recommendation
Powered by
MediGene AG Classifications & Recommendation:
Hold
100%
MediGene AG Price Target
| Target Price | €2.00 |
| Price | €0.13 |
| Potential |
1,438.46%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a MediGene AG price target 2026.
The average MediGene AG target price is €2.00.
This is
1,438.46%
register free of charge
|
|
| A rating was issued by 1 analysts: 0 Analysts recommend MediGene AG to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the MediGene AG stock has an average upside potential 2026 of
1,438.46%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million € | 6.03 | 9.50 |
| 80.70% | 57.55% | |
| EBITDA Margin | -249.25% | -142.49% |
| 711.88% | 42.83% |
2 Analysts have issued a sales forecast MediGene AG 2024 . The average MediGene AG sales estimate is
€9.5m
Unlock
27.52%
higher
Unlock
€11.0m
47.65%
Unlock
€8.0m
7.38%
Unlock
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast MediGene AG 2024 . The average MediGene AG EBITDA estimate is
€-13.5m
Unlock
5.07%
higher
Unlock
€-13.5m
5.07%
Unlock
€-13.5m
5.07%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | €-15.0m | 218.07% |
|---|---|---|
| 2024 |
€-13.5m
9.93%
Unlock
|
|
EBITDA Margin
| 2023 | -249.25% | 711.88% |
|---|---|---|
| 2024 |
-142.49%
42.83%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| EV/Sales | negative |
Current MediGene AG Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Dec 15 2024 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 29 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Dec 15 2024 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 29 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
